Pfizer’s Ibrance ‘unlikely’ to hit key early breast cancer goal
The trial is unlikely to show a statistically significant improvement in invasive disease-free survival
Read More
Tag: palbociclib
Pairing targeted drugs could overcome breast, lung cancer treatment resistance
The new data could broaden the clinical use of palbociclib – and other drugs that work in the same way – beyond breast cancer to include many other tumour types as well.
Read More
NICE rejects Lilly’s breast cancer drug Verzenios
As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug.
Read More
Scotland approves NHS funding for Ibrance, Cerdelga and Invicorp
The latest batch of decisions by the Scottish Medicines Consortium has given patients with certain forms of breast cancer, Gaucher disease and erectile dysfunction new treatment options on the NHS.
Read More
NICE waves through breast cancer drugs following price deals
The National Institute for Health and Care Excellence is backing routine NHS funding for Pfizer’s Ibrance and Novartis’ Kisqali to treat certain forms of breast cancer, after the firms agreed to provide them at a reduced price under the new process for appraising medicines.
Read More
EU, US approvals for Faslodex combinations
AstraZeneca’s Faslodex has been cleared on both sides of the Atlantic for use in combination with a CDK4/6 inhibitor.
Read More
Pfizer offers Ibrance free to the NHS during NICE appraisal
Pfizer is to offer its breast cancer drug Ibrance free to the NHS while cost regulators decide whether it should be routinely funded in England and Wales.
Read More
Pfizer bags EU approval for breast cancer drug Ibrance
European regulators have cleared use of Pfizer’s Ibrance to treat women with locally advanced or metastatic breast cancer that is hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
